Last updated: February 24, 2026
What is the Drug with NDC 62559-0280?
The National Drug Code (NDC) 62559-0280 is designated for a specific pharmaceutical product. Based on available databases, this NDC corresponds to Ruxolitinib (brand name: Jakafi), used primarily for treating myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD).
Market Size and Dynamics
Current Market Scope
- Global Market Value: Estimated at approximately USD 1.2 billion in 2022.
- U.S. Sales: Approximate USD 800 million, accounting for 67% of the global market.
- Patient Population: Roughly 20,000 to 30,000 U.S. patients affected by myelofibrosis or polycythemia vera, eligible for ruxolitinib therapy.
Competitive Landscape
- Key Competitors: Fedratinib (Inrebic),Pacritinib, and emerging JAK inhibitors.
- Market Share: Ruxolitinib holds approximately 65-75% of the JAK inhibitor market segment.
- Pipeline Products: Several late-stage compounds targeting similar pathways, expected to influence future market dynamics.
Regulatory and Reimbursement Factors
- FDA Approval: Originally approved in 2011.
- Reimbursement: Covered by Medicare, Medicaid, and most private insurers with high reimbursement rates, supporting steady sales.
- Pricing Policies: Fierce pricing battles influence list vs. net prices, with list prices around USD 15,000-USD 20,000 per month.
Price Analysis and Projections
Current Pricing Trends
- Average Wholesale Price (AWP): Approximately USD 18,000 per month.
- Net Price: Estimated at 30-50% below list prices due to rebates and discounts.
- Cost per Treatment Course: Around USD 200,000 annually per patient.
Price Drivers
- Demand Stability: Chronic indication fosters consistent demand.
- Patent Status: Patent protection until 2026; biosimilar competition expected to emerge thereafter.
- Pricing Pressure: Cost-control initiatives and biosimilar entry could reduce prices by 10-20% over the next 3-5 years.
Future Price Projections (2023-2028)
| Year |
Estimated List Price |
Expected Discount Rate |
Projected Net Price |
Rationale |
| 2023 |
USD 18,000/month |
30% |
USD 12,600/month |
Current market conditions |
| 2024 |
USD 17,400/month |
35% |
USD 11,310/month |
Slight price erosion from rebates |
| 2025 |
USD 16,800/month |
40% |
USD 10,080/month |
Biosimilar competition increasing |
| 2026 |
USD 16,200/month |
45% |
USD 8,910/month |
Patent expiry approaches, biosdwither impact |
| 2027 |
USD 15,600/month |
50% |
USD 7,800/month |
Market saturation, biosimilar proliferation |
Long-term Outlook
Post-patent expiry, biosimilars could reduce net prices by 30-50%. The availability of generics will likely slow revenue growth, but the drug's established efficacy may preserve a substantial share of the market.
Regulatory and Reimbursement Impact
- Price containment policies globally, especially in Europe and the U.S., will influence future pricing.
- Reimbursement policies favor continued use, but cost-effectiveness assessments may tighten prices, especially with emerging competitors.
Risks and Opportunities
- Risks: Patent cliffs, biosimilar competition, cost containment efforts.
- Opportunities: Expanded indications, combination therapies, pipeline advancements.
Key Takeaways
- Ruxolitinib (NDC 62559-0280) dominates the JAK inhibitor market for myeloproliferative diseases.
- Current average annual treatment costs approximate USD 200,000 per patient.
- Prices are expected to decline gradually due to biosimilar entry and policy pressures, with net prices potentially dropping 10-20% in the next 3-5 years.
- Market growth is steady, driven by chronic disease prevalence and expanding indications.
- Patent expiration in 2026 will trigger significant price and market share adjustments.
FAQs
Q1: What factors primarily influence ruxolitinib's pricing?
A1: Patent status, competition, reimbursement policies, and demand stability.
Q2: How will biosimilar competition affect prices?
A2: Biosimilars could cut net prices by 30-50%, exerting downward pressure.
Q3: What is the projected market value for ruxolitinib through 2028?
A3: The market is expected to remain around USD 1 billion annually, decreasing gradually post-2026 due to biosimilar entry.
Q4: What are key growth opportunities for this drug?
A4: New indications, combination therapies, and pipeline development.
Q5: How do reimbursement policies impact future price projections?
A5: They influence net prices through formulary decisions, coverage, and cost-effectiveness assessments.
References
- IQVIA. (2022). Pharmaceutical Market Data.
- FDA. (2011). FDA Approvals and Labeling for Ruxolitinib.
- Evaluate Pharma. (2022). Market Forecasts and Pipeline Updates.
- Centers for Medicare & Medicaid Services. (2022). Reimbursement Data.
- Scrip Pharma Intelligence. (2022). Competitive Landscape and Biosimilar Entry.
